GSK Kills Camlipixant: $2B Bellus Loss, P2X3 Dead for Cough

GSK (GSK) discontinued development of camlipixant in refractory chronic cough on July 17, 2026, after the Phase 3 CALM-2 trial failed to confirm the efficacy seen in CALM-1. The decision writes off a $2 billion acquisition of Bellus Health completed in April 2023, and it effectively kills the P2X3 receptor antagonist class for chronic cough.

GSK closed at $51.35 on July 24, with a market cap near $103 billion. The stock absorbed the news without a sharp move, because the failure was already telegraphed by the mixed Phase 3 readouts.

What the data showed

CALM-1 met its primary endpoint: the 50 mg twice-daily dose produced a statistically significant reduction in 24-hour cough frequency versus placebo at Week 12. CALM-2 did not replicate that result. The 25 mg dose lacked efficacy in both trials, and key secondary endpoints, including the Chronic Cough Diary measure, were missed across the board. GSK concluded that “the limited efficacy demonstrated is unlikely to transform patient care” and stopped the program.

GSK is continuing a Phase 2b BALANCE trial testing camlipixant in irritable bowel syndrome with diarrhea, but the chronic cough indication, which carried the bulk of the commercial thesis, is gone.

Why this matters

Camlipixant is the third P2X3 antagonist to fail in chronic cough. Merck’s gefapixant was rejected by the FDA twice, most recently in December 2023, with the agency citing insufficient evidence of effectiveness. Bayer’s eliapixant also stalled. Three pharma giants collectively spent well over $3 billion chasing the same mechanism, and none delivered an approved drug in the US.

P2X3 receptors sit on airway nerves, which are present at higher density in chronic cough patients. Blocking them should reduce cough sensitivity. The mechanism is biologically plausible, and Phase 2 signals were strong enough to justify Phase 3 investment. The repeated Phase 3 failures suggest either that the cough reflex arc is too redundant for a single receptor target to modify durably, or that the subjective, variable nature of cough measurement defeats trial designs built on 24-hour frequency endpoints.

Who benefits

Trevi Therapeutics (TRVI) is the immediate beneficiary. Its Haduvio (oral nalbuphine ER) works on a different mechanism, acting on opioid receptors in the cough reflex arc as a kappa agonist and mu antagonist. TRVI shares rose roughly 12% on the GSK news. Haduvio has shown statistically significant cough frequency reductions in both IPF chronic cough (Phase 2b CORAL) and refractory chronic cough (Phase 2a RIVER). With the P2X3 field cleared, Trevi faces no direct mechanism-of-action competition in US chronic cough development.

The risk for Trevi: it is still in Phase 2, and the P2X3 saga is a cautionary tale about Phase 2-to-3 translation in this indication. A guide to reading clinical trial press releases covers how to interpret these data drops without overreacting.

What to watch

GSK’s broader pipeline gap is the story for GSK investors. The company’s £40 billion 2031 revenue target relied partly on camlipixant’s projected £2.5 billion in peak sales, which is now zero. Watch whether GSK redeployes the R&D spend or pivots to business development. The GSK press release and Endpoints coverage are the primary sources.

What It Means for the Trade

For GSK holders, this is a write-off the market had mostly pre-absorbed: the stock barely moved because CALM-1’s mixed readout had already telegraphed the risk, and a $103 billion company can eat a $2 billion deal without a re-rating. The strategic cost is what matters — a projected £2.5 billion peak-sales line in the £40 billion 2031 revenue plan went to zero, and the question for the stock is whether GSK’s business-development machine can replace it. Watch redeployment signals: bolt-on M&A or accelerated pipeline spend would tell you the R&D budget is being recycled rather than banked. The class-level lesson is the more durable takeaway: three P2X3 failures across Merck, Bayer, and GSK — well over $3 billion combined — mean no serious pharma will re-enter chronic cough via this mechanism soon. That is a moat-by-default for whoever is next, and the market immediately repriced Trevi 12% on exactly that logic.

Mechanism and Market Context

P2X3 receptors on airway vagal nerves fire the afferent limb of the cough reflex, and chronic cough patients have heightened airway-nerve density that plausibly amplifies that signal — the biology was good enough to carry three programs into Phase 3. What kept failing was translation: 24-hour cough-frequency endpoints are noisy, placebo responses run high, and CALM-1’s win did not survive replication in CALM-2, while the 25 mg dose lacked efficacy in both trials. Two competing explanations — a reflex arc too redundant for one receptor to modify durably, or a measurement problem that defeats the trial design — point to the same conclusion: the indication is de-risked for nobody, and the next challenger (Trevi’s opioid-mechanism Haduvio) still faces the same Phase 2-to-3 translation risk that killed the P2X3 class. GSK’s residual exposure is the Phase 2b BALANCE trial in IBS-D, a much smaller and unproven thesis.

Risks and What Could Go Wrong

1. For TRVI longs riding the 12% repricing: Haduvio is Phase 2, in an indication that has now burned three Phase 3 programs — the class cautionary tale applies directly.
2. For GSK: repeated high-profile pipeline misses invite investor pressure on the 2031 revenue target’s credibility, and each write-off narrows the margin for error.